Generalized bullous fixed drug eruption (GBFDE) most commonly refers to a drug reaction in the erythema multiforme group.[3]: 129 These are uncommon reactions to medications, with an incidence of 0.4 to 1.2 per million person-years for toxic epidermal necrolysis and 1.2 to 6.0 per million person-years for Stevens–Johnson syndrome.[3]: 129 The primary skin lesions are large erythemas (faintly discernible even after confluence), most often irregularly distributed and of a characteristic purplish-livid color, at times with flaccid blisters.[2]: 554
Signs and symptoms
A rare and severe variation of fixed drug eruption, generalized bullous fixed drug eruption involves blisters and erosions involving at least 10% of the body's surface area, affecting three of the six anatomic sites: the head and neck, the anterior and posterior trunk, the upper and lower extremities, and the genitalia.[4]
In cases where the clinical presentation is unclear, a skin biopsy may be necessary to confirm the diagnosis of GBFDE. A subepidermal blister or denuded epidermis, vacuolar alterations at the dermo-epidermal junction, and a variable number of necrotic keratinocytes within the lesional intact epidermis are characteristic histopathologic findings of GBFDE.[5]
Treatment
Antihistamines and topical steroids are used in symptomatic therapy. Antibiotics should be given if an infection is thought to be present.[6] It is also important to counsel the patient to stay away from the offending medication.[7]
Cho, Yung-Tsu; Lin, Jheng-Wei; Chen, Yi-Chun; Chang, Chia-Ying; Hsiao, Cheng-Hsiang; Chung, Wen-Hung; Chu, Chia-Yu (2014). "Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features". Journal of the American Academy of Dermatology. 70 (3). Elsevier BV: 539–548. doi:10.1016/j.jaad.2013.11.015. ISSN0190-9622. PMID24388722.